Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Bispecific Antibodies Propel the Relapsed/Refractory Myeloma Paradigm Further Ah...
Timothy M. Schmidt, MD, discusses the integration and utility of bispecific antibodies in relapsed/refractory multiple myeloma, as well as some of the most promising agents in clinical development.
CAR-T Explodes on the Scene in Heavily Pretreated Multiple Myeloma
Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.
Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell Lymphoma
For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.
Optimizing care with CAR T-cell therapy now and in the future for patients with ...
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.
Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Acti...
Cord blood–derived natural killer (NK) immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant (ASCT), showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma (NHL), according to data from a phase 2 trial (NCT03019640) presented in a poster during the 2021 Transplant & Cellular Therapy Meetings.
Tisagenlecleucel Leads to High CR Rate in Heavily Pretreated, R/R Follicular Lym...
Tisagenlecleucel induced a significant number of complete responses in patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the phase 2 ELARA trial as of the interim analysis of the study.
Trispecific antibody targets cancer cells, natural killer cells
Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof. Novel treatments with minimum side effects are one of the main aims of the ongoing cancer research.
Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma
Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.
How do I manage the risk of infection in patients treated with immunotherapies?
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?